Sellas Life Sciences Stock Soars 15% on Clinical Trial Buzz
July 2, 2026·about 3 hours ago·via Stocktwits
Biotech company Sellas Life Sciences is drawing significant attention from retail traders as investors eye upcoming Phase 3 clinical trial results. The stock has surged 15 percent as market enthusiasm builds around the REGAL catalyst. Traders are closely watching the company's progress, making it a hot topic in investment communities tracking biotech developments. Read more about this...